COVID-19 Post-hospital Thrombosis Prevention Study
Anticoagulant Agent vs. Placebo
Adults > 18 years of age with COVID-19 who are hospitalized for 48 hours or longer and who are ready for discharge from the hospital
Anticoagulation: Apixaban 2.5 mg
5,320 in total (2,270 to each treatment arm) for Stage 1
Power and Interim Assessments
In order to ensure an 80% power to detect a CE rate reduction of 35% through anticoagulation use, the study needs to enroll at least 2,530 participants per arm.
At least through Day 90 with visits at Days 2, 10, 20, 30, 45 and 90.